Results 91 to 100 of about 46,923 (257)

IgG4-related autoimmune disease : imaging findings [PDF]

, 2013
IgG4 autoimmune disease (or hyper IgG4 disease) is a relatively recently described systemic disease that is characterised by abundant infiltration of IgG4-positive plasma cells and lymphocytes with associated fibrosis leading to organ dysfunction ...
Vassallo, Pierre
core  

Stillbirth in pregnancies with flat OGTT: Placental clues to occult maternal dysmetabolism

International Journal of Gynecology &Obstetrics, EarlyView.
Emma Bertucci, Alessandra Danieli, Francesco Ricciardiello, Isabella Neri, Francesca Monari, Alessandro D. Genazzani, Gaetano Bulfamante, Antonio La Marca, Laura Botticelli, Fabio Facchinetti, Laura Avagliano   +10 more
wiley   +1 more source

Teplizumab in Stage 2 Type 1 Diabetes: Clinical Practice Experience on Feasibility in 3 Adult Patients

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim To describe the first Italian experience with teplizumab administered under a compassionate use programme for adults with Stage 2 type 1 diabetes (T1D), and to evaluate its feasibility, safety and early metabolic outcomes in a real‐life clinical setting outside formal clinical trials.
V. Guarnotta, F. Pantò, E. Vigneri, G. Piombo, M. I. Mineo, L. Tomasello, G. Arnaldi   +6 more
wiley   +1 more source

Assessment of autoimmune thyroiditis in Turkish children with celiac disease

Gülhane Tıp Dergisi
Aims: It has been reported that there is a link between celiac disease and other autoimmune diseases in children. We aimed to compare the presence of autoimmune thyroid disease in children with celiac disease and the ultrasonographic evaluations of these
Coşkun Fırat Özkeçeci, Melike Arslan, Edibe Gözde Başaran, Semra İnce, Sevinç Odabaşı Güneş, Necati Balamtekin   +5 more
doaj   +1 more source

Chronic autoimmune thyroiditis and obesity [PDF]

Archives of the Balkan Medical Union, 2018
Chronic autoimmune thyroiditis (Hashimoto’s thyroiditis) is the most common cause of hypothyroidism which may associate weight increase and changes in serum lipid levels.
Ana Valea, Mara Carsote, Cristina Moldovan, Carmen Georgescu   +3 more
doaj  

Clinical heterogeneity in vitiligo: Identification of clinical markers based patient clusters

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Vitiligo is a chronic autoimmune disease with heterogeneous clinical presentations. This study analysed 399 patients using hierarchical clustering and identified five phenotypes based on clinical characteristics and lesion distribution. Two groups exhibited high disease activity and extensive involvement.
Laura Galissi, Tristan Benoît, Ribal Merhi, Claire Drullion, Nicolas Andreu, Khaled Ezzedine, Thomas Darde, Katia Boniface, Julien Seneschal   +8 more
wiley   +1 more source

Anti-Müllerian hormone: Predictor of premature ovarian insufficiency in Egyptian women with autoimmune thyroiditis

Middle East Fertility Society Journal, 2018
Background: Menopause associated with hormone-sensitive co-morbidity such as breast cancer, endometrial cancer, osteoporosis, and cardiovascular disease. Autoimmunity is one of the leading causes of primary ovarian insufficiency (POI). Thyroiditis is the
Nearmeen M. Rashad, Hala Moafy, Hend S. Saleh, Abdelaziz I. Amin, Ahmed F. Gomaa   +4 more
doaj   +1 more source

Real‐world efficacy and toxicity of ipilimumab and nivolumab as a first‐line treatment for advanced renal cell carcinoma according to IMDC risk criteria—A multi‐center retrospective analysis on behalf of the GUARDIANS group

International Journal of Cancer, Volume 158, Issue 9, Page 2440-2451, 1 May 2026.
What's new? The combination of ipilimumab and nivolumab as a first‐line treatment for advanced renal cell carcinoma has demonstrated durable response and tolerability in clinical trials. However, inclusion criteria for clinical studies are restrictive, and patients in the real‐world setting tend to have more comorbidities.
Hendrik Dinkel, Linus Materna, Ramona Stelmach, Stefanie Zschäbitz, Stephanie Neuberger, Can D. Aydogdu, Jozefina Casuscelli, Timo Egenolf, Matteo Silberg, Julie Steinestel, Arne Strauss, Florian Kirchhoff, Marit Ahrens, Pia Paffenholz, Richard Cathomas, Berna C. Özdemir, Christopher Gossler, Philipp Ivanyi, Marc Rehlinghaus, Thomas Hilser, Viktor Grünwald, Katrin Schlack   +21 more
wiley   +1 more source

Roles of GM-CSF in the Pathogenesis of Autoimmune Diseases: An Update. [PDF]

, 2019
Granulocyte-macrophage colony-stimulating factor (GM-CSF) was first described as a growth factor that induces the differentiation and proliferation of myeloid progenitors in the bone marrow.
Adorini, Ahn, Alnek, Ananthakrishnan, Aram, Aricha, Basdeo, Bernasconi, Bezbradica, Bhattacharya, Bhattacharya, Bogunovic, Borriello, Campbell, Cao, Casciola-Rosen, Cheatem, Chiewchengchol, Choi, Chuang, Ciric, Codarri, Cook, Cook, Coombes, Croxford, Denson, Derouet, Dieckgraefe, Duhen, Egea, El-Behi, Enzler, Fernandes, Fillatreau, Fraussen, Fuchs, Ganesan, Ganesh, Gangi, Gao, Gathungu, Gaudreau, Ghosh, Gonzalez, Gopisetty, Hansen, Harrington, Hartmann, Hirota, Hirota, Hirota, Huang, Imitola, Jain, Kared, Karni, Kaskow, Katano, Katz, Kelly, Kenkel, King, King, Kister, Lebre, Lee, Lehtonen, Leizer, Li, Li, Li, Li, Makris, Marks, Matsuyama, Mausberg, McWilliams, Meriggioli, Midgley, Mikita, Mufazalov, Muranski, Nagane, Noster, Ortega, Parajuli, Pare, Pare, Park, Piper, Ponomarev, Poppensieker, Ramos-Levi, Rasouli, Reynolds, Roelofs, Rowin, Sakaguchi, Salehi, Samarpita, Scholz, Schutt, Serafini, Shang, Shapouri-Moghaddam, Sheng, Sheng, Sheng, Shiomi, Shiomi, Shiomi, Smith, Srenathan, Stojic-Vukanic, Surendar, Tavakolpour, Touil, Tsark, van de Laar, van Nieuwenhuijze, Vasu, Vincent, Vincent, Vogel, Waisman, Wicks, Wiggins-Dohlvik, Willeke, Xu, Xu, Yang, York, Zhang, Zhao   +134 more
core   +2 more sources

Clinical Safety of Extended Interval Dosing of Nivolumab in Patients with Melanoma

Clinical Pharmacology &Therapeutics, Volume 119, Issue 4, Page 997-1004, April 2026.
Extended interval dosing regimens of immune checkpoint inhibitors have been implemented widely. However, their approval was mainly based on pharmacokinetic modeling and simulations. Consequently, comparative safety data of extended interval dosing regimens in a real‐world setting are limited.
Ruben Malmberg, Maaike M. Hofman, Fatima Ashad, Alaa Daloul, Stefani Oosterveld, Edwin A. Basak, Esther Oomen‐de Hoop, Astrid A. M. van der Veldt, Arjen Joosse, Roelof W. F. van Leeuwen, Ron H. J. Mathijssen   +10 more
wiley   +1 more source